Lee's Pharmaceutical Holdings Ltd
HKEX:950
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Lee's Pharmaceutical Holdings Ltd
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture and sale of pharmaceutical products. The firm operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The firm mainly operates businesses in China and Hong Kong.
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture and sale of pharmaceutical products. The firm operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The firm mainly operates businesses in China and Hong Kong.
